6533b7cffe1ef96bd1258683
RESEARCH PRODUCT
Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?
Evangelos LiberopoulosManfredi RizzoJames J. DinicolantonioF. Barkassubject
Cancer preventionIsoprenoid synthesisbusiness.industryCholesterolEndocrinology Diabetes and Metabolismnutritional and metabolic diseasesContext (language use)Pharmacologyanticancer drugs cancer chemotherapeutics statins tumorchemistry.chemical_compoundchemistryAntithromboticMedicinelipids (amino acids peptides and proteins)cardiovascular diseasesCardiology and Cardiovascular Medicinebusinessdescription
ISSN 1758-4299 10.2217/CLP.13.29 © 2013 Future Medicine Ltd Clin. Lipidol. (2013) 8(3), 273–277 Pleiotropic effects of statins Millions of patients worldwide are currently tak ing prescribed statins. Clinical trials have dem onstrated that statins reduce the risk of cardio vascular disease [1]. Statins are well known to reduce cholesterol levels through the inhibition of 3hydroxymethylglutaryl CoA reductase [2]. However, great interest has recently been paid to the mechanisms beyond cholesterol reduc tion (pleiotropic effects) by which statins exert their action. Indeed, statins are associated with plaque stabilization and improvement of endo thelial function, as well as antiinflammatory, antioxidative and antithrombotic effects [3,4]. Some of the pleiotropic effects of statins are mediated through the inhibition of isoprenoid synthesis, which serve as substrates for the post transcriptional modification of many proteins [4]. In this context, the possible anticancer effects of statins have attracted a lot of interest recently.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-06-01 | Clinical Lipidology |